Well-tolerated compound holds potential hope for the treatment of Huntington’s disease

Written by Alice Weatherston

In a new study, published recently in Nature Medicine, researchers have presented findings highlighting a compound termed KD3010 as a potentially effective treatment for slowing Huntington’s disease (HD) symptoms and decline. The compound was previously tested for use in the treatment of diabetes in a Phase Ib trial where it was well-tolerated in participants. “We’re very excited by our preclinical testing of this compound (KD3010),” commented lead author Albert La Spada (University of California, San Diego, USA). Following previous discovery of the significant role of PGC-1 alpha, a regulatory protein central to the creation and operation of mitochondria, as well...

To view this content, please register now for access

It's completely free